Võrdle meetodeid
Vaata valitud meetodeid kõrvuti; erinevad read on esile tõstetud.
| Tahke dispersioon (Solid Dispersion Formulation)× | Liposoomne ravimikandja× | |
|---|---|---|
| Valdkond | Farmakoloogia | Farmakoloogia |
| Perekond | Process / pipeline | Process / pipeline |
| Tekkeaasta≠ | 1971 | 1965 |
| Looja≠ | William Chiou and Solomon Riegelman | Alec Bangham |
| Tüüp≠ | solubility enhancement | formulation technology |
| Algallikas≠ | Chiou, W. L., Riegelman, S. (1971). Pharmaceutical applications of solid dispersions. Journal of Pharmaceutical Sciences, 60(9), 1281-1302. link ↗ | Bangham, A. D., Standish, M. M., & Watkins, J. C. (1965). Diffusion of univalent ions across the lamellae of swollen phospholipid films and the determination of membrane potential. Journal of Molecular Biology, 13(1), 238-252. DOI ↗ |
| Rööpnimetused | solid solution, amorphous dispersion, polymer-based formulation | liposomal formulation, vesicular delivery, lipid nanoparticles |
| Seotud | 3 | 3 |
| Kokkuvõte≠ | Solid dispersion is a formulation technique where a poorly soluble drug is molecularly dispersed in a hydrophilic polymer matrix, improving aqueous solubility and bioavailability. Introduced by Chiou and Riegelman in 1971, solid dispersions remain a key strategy for overcoming solubility-limited absorption. | Liposomal encapsulation is a formulation technique using lipid bilayer vesicles (liposomes) to enclose drugs, improving bioavailability, reducing toxicity, and enabling targeted delivery. Developed by Alec Bangham in 1965, liposomes are now standard in pharmaceutical development, with several FDA-approved liposomal drugs on the market. |
| ScholarGateAndmestik ↗ |
|
|